A significantly higher proportion of non-BRCA1/2 carriers (40.0%) had axillary lymph node metastases (stages II–III) compared with both BRCA1/2 carriers (14.3%) and non-carriers (12.2%, p = 0.023). Here, BRCA1 is linked to metastatic malignant neoplasm in the lymph nodes.